We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
- Authors
In-Jae Oh; Jae Young Hur; Cheol-Kyu Park; Young-Chul Kim; Seung Joon Kim; Min Ki Lee; Hee Joung Kim; Kye Young Lee; Jae Cheol Lee; Chang-Min Choi; Oh, In-Jae; Hur, Jae Young; Park, Cheol-Kyu; Kim, Young-Chul; Kim, Seung Joon; Lee, Min Ki; Kim, Hee Joung; Lee, Kye Young; Lee, Jae Cheol; Choi, Chang-Min
- Abstract
<bold>Introduction: </bold>HER2 mutations are found in 2% to 4% of non-small-cell lung cancer cases and are usually mutually exclusive with other genetic alterations. We screened a large cohort of patients from multiple institutions in Korea, described the characteristics of HER2-mutant cases, and reported on several patients who were treated with pan-HER inhibitors.<bold>Patients and Methods: </bold>The study population consisted of 360 patients diagnosed with adenocarcinoma from 4 institutions in Korea from June 2015 to September 2016. Tissue specimens from all participants were screened by direct sequencing, and next-generation sequencing was conducted only on specimens that were positive in direct sequencing. HER2-targeted therapy, either poziotinib or afatinib, was orally administrated.<bold>Results: </bold>Next-generation sequencing was conducted in 129 patients, and finally 29 (8.1%) patients with HER2 mutation were identified. Most patients were female (58.6%), had never smoked (70.0%), and had stage IV non-small-cell lung cancer (55.2%). For all patients, the histologic type was adenocarcinoma, with no coexisting EGFR or ALK alterations. The most common type of HER2 mutation (48.3%) was c.2326_2327insTGT in exon 20. A partial response was observed in 2 patients who received poziotinib and 1 patient who received afatinib. The main toxicities of the pan-HER inhibitors were nausea, diarrhea, and mucositis.<bold>Conclusion: </bold>HER2 mutation was estimated at a frequency of approximately 8.1% in Korean patients with adenocarcinoma in the absence of known driver mutations. Because some of the HER2-mutant cases responded to poziotinib or afatinib, further studies are warranted.
- Subjects
HETEROCYCLIC compounds; ADENOCARCINOMA; CELL receptors; COMPARATIVE studies; LONGITUDINAL method; LUNG cancer; LUNG tumors; RESEARCH methodology; MEDICAL cooperation; GENETIC mutation; PROGNOSIS; RESEARCH; SURVIVAL; EVALUATION research; RETROSPECTIVE studies; SEQUENCE analysis
- Publication
Clinical Lung Cancer, 2018, Vol 19, Issue 5, pe775
- ISSN
1525-7304
- Publication type
journal article
- DOI
10.1016/j.cllc.2018.05.018